A Phase 3 interventional study of Mirikizumab in Ulcerative Colitis, sponsored by Eli Lilly and Company. Active, not recruiting at 352 sites in 36 countries. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-04-20.
Sponsored by Eli Lilly and Company · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 13 studies testing mirikizumab in Colitis, Ulcerative — 4 open to participants now, 5 under way, 2 of them phase 3. mirikizumab · Colitis, Ulcerative.
Among the 13 studies testing mirikizumab in Colitis, Ulcerative, this one is the 3rd largest by enrollment, is one of 3 that started in 2018, is one of 7 in phase 3, and was the 3rd registered.
1,854 studies on the registry are indexed under Colitis, Ulcerative; 473 are open to participants now.
Browse Colitis, Ulcerative studies →4 of the 13 studies testing mirikizumab in Colitis, Ulcerative are open now, in 12 countries. Recruiting first, the newest first:
University Hospital Schleswig-Holstein · Sites in Germany
Ages 18–75
Eli Lilly and Company · Sites in United States, Austria, Belgium and 13 more countries
Ages 2–19
Specialty Networks Research. · Sites in United States
Ages 21+
Rubix LS · Sites in United States
Ages 60–99
By country, each count listing its studies:
mirikizumab: first FDA approval 2023 (OMVOH), first EMA approval 2023. What it is approved for, and how studies give it, is on its page →
Of the 307 Colitis, Ulcerative studies recruiting now, 134 (44%) set no upper age limit and 136 (44%) stop at 75 or younger; 71 take children under 18; 41 take healthy volunteers.
This study: 18 Years to 80 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
13 studies; the count open now beside each. This study's row is marked.
First in 2015; this study’s year is marked. 3 started in 2018.
This study's enrollment of 1,058 is above the median of 70 across 1,237 interventional studies indexed under Colitis, Ulcerative.
Median enrollment 172 across the 13 interventional studies. Of the 7 that completed or were terminated, 5 (71%) have results posted.
This tab as a report to print or save as PDF → With an account.
10 of 13 have an industry lead sponsor. The 5 most frequent:
Eli Lilly and Company is the lead sponsor of 2,108 studies on the registry; 153 are open to participants now.
Of its 537 completed or terminated interventional studies of FDA-regulated products, 358 (67%) have results posted.
16 studies in Colitis, Ulcerative by Eli Lilly and Company: 5 open now, 7 under way, 3 of them phase 3. Of 8 finished, 7 (88%) have results posted.
Among the 16 studies in Colitis, Ulcerative by Eli Lilly and Company, this one is the 4th largest by enrollment, is one of 3 that started in 2018, is one of 8 in phase 3, and was the 3rd registered.
Eli Lilly and Company’s Colitis, Ulcerative studies by the year they started, since 2015.
None of the studies under way reaches primary completion within a year.
Among the 13 studies testing mirikizumab in Colitis, Ulcerative, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Eli Lilly and Company’s 16 in Colitis, Ulcerative:
This tab as a report to print or save as PDF → With an account.
This study is designed to evaluate the long-term efficacy and safety of mirikizumab in participants with moderately to severely active ulcerative colitis (UC). The study will last up to 3 years. Participants who complete the 3-year study may continue to receive mirikizumab until it is (outside of this study) in their country or until they meet other discontinuation criteria.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Participants from Study AMAC (NCT02589665) or AMBG (NCT03524092) who have had at least one study drug administration and have not had early termination of study drug.
Participants must not have developed a new condition, including cancer in the originator study.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Mirikizumab administered subcutaneously (SC).
Drug: Mirikizumab
Administered SC.
Also known as: LY3074828
Percentage of Participants in Clinical Remission
Clinical remission based on the modified Mayo Score (MMS).
Time frame: Week 52
Percentage of Participants in Endoscopic Remission
Endoscopic remission based on the MMS Endoscopic Subscore (ES).
Time frame: Week 52
Percentage of Participants in Corticosteroid-free Remission
Participants in corticosteroid-free remission.
Time frame: Week 52
Percentage of Participants with Histologic-Endoscopic Mucosal Remission at Week 52
Endoscopic remission based on the MMS ES and histologic remission based on histologic disease activity index.
Time frame: Week 52
Health Related Quality of Life: Inflammatory Bowel Disease Questionnaire (IBDQ) Score
Health Related Quality of Life based on IBDQ score.
Time frame: Baseline to Week 52
UC Symptoms: Numeric Rating Score
UC symptoms based on numeric rating score.
Time frame: Week 160
Percentage of Participants Who are Hospitalized Due to UC
Participants who are hospitalized due to UC.
Time frame: Baseline to Week 160
Percentage of Participants Who Undergo UC Surgeries Including Colectomy
Participants who undergo UC surgeries including colectomy.
Time frame: Baseline to Week 160
Showing the first 100 of 352 sites across 36 countries. Choose a country and city above to see the rest.
Plan to share: Yes — Lilly provides access to the individual patient data from studies on approved medicines and indications as defined by the sponsor specific information on ClinicalStudyDataRequest.com. This access is provided in a timely fashion after the primary publication is accepted. Researchers need to have an approved research proposal submitted through ClinicalStudyDataRequest.com. Access to the data will be provided in a secure data sharing environment after signing a data sharing agreement.
Ran from Jul 2018 to primary completion in Mar 2026, 91 months.
Of 87 industry-sponsored phase 3 interventional studies under Colitis, Ulcerative, half reached primary completion within 47 months of starting (the median), counting those still running; a quarter within 31 and three quarters within 70. This study's 91 months is above that.
Counting every sponsor, half of 101 studies reached it within 48 months; a quarter within 31 and three quarters within 75.
How these figures are worked out, and which studies are left out of them.
This study is active, not recruiting, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Mirikizumab